Full Year 2025 Scancell Holdings PLC Earnings Call Transcript
Key Points
- Scancell Holdings PLC (SCNLF) formed a major partnership with the Cancer Vaccine Launchpad, highlighting significant progress in their cancer vaccine development.
- The iSCIB1+ product from the SCOPE study showed a progression-free survival (PFS) rate of 78% in advanced melanoma, significantly higher than the historical standard of care.
- The company has successfully submitted documentation to the FDA and other regulators for randomized studies towards registration for iSCIB1+, indicating progress in regulatory processes.
- Scancell Holdings PLC (SCNLF) has established a commercial-scale manufacturing process for iSCIB1+, ensuring high-quality formulation and long-term stability.
- The company raised GBP12.1 million in financing, strengthening its financial position and supporting further development efforts.
- Research and development expenses increased to GBP14.7 million, reflecting higher costs associated with clinical and manufacturing activities.
- The company reported an operating loss of GBP15 million, despite revenue from licensing agreements.
- There is uncertainty regarding the alignment of trial design and endpoints among regulatory agencies like the FDA, EMA, and MHRA, which could impact study protocols.
- The company has not yet secured funding for the full iSCIB1+ registration trial, indicating a potential financing gap.
- Scancell Holdings PLC (SCNLF) faces challenges in share price performance, attributed to low trading volumes and compliance-related selling by institutional investors.
Good afternoon, ladies and gentlemen, and welcome to Scancell Holdings plc full-year results. (Operator Instructions). I would like to remind all participants that this call is being recorded.
I will now hand over to Mary-Ann from Investor Relations to open the presentation. Please go ahead.
Good morning, and good afternoon to all our listeners. It's my pleasure to welcome you to Scancell's results call for the year ended April 30, 2025. My name is Mary-Ann Chang, Investor Relations for Scancell.
With us presenting today, we have Phillip L'Huillier, our CEO; and Sath Nirmalananthan, our CFO. Following the presentation, we'll be taking questions directly from analysts as well as written questions from our audience, which you may submit at any point during the webcast. Next slide, please.
Before we begin, I'd like to draw everyone's attention to this statement. Today's discussion will include forward-looking statements, which are based on current
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
